This is a rare opportunity to acquire a fully permitted, large-scale pharmaceutical-grade manufacturing facility in the United States. Located in Columbus, Georgia, the site is strategically positioned to support domestic API production and strengthen U.S. pharmaceutical supply chains. The opportunity is structured to provide flexibility of acquisition, allowing buyers to pursue the asset either as a standalone real estate investment or as a turnkey pharmaceutical manufacturing platform, depending on strategic objectives. Real Estate Acquisition Land and Facility Only The real estate offering consists of a 22-acre industrial site with a purpose-built pharmaceutical manufacturing facility. This option enables an owner or investor to acquire the land and building independently of the manufacturing equipment and operational assets. The facility encompasses approximately 50,000 square feet, offering significant flexibility for continued pharmaceutical use, redevelopment, or repurposing for other advanced manufacturing applications. The property benefits from clean Phase I and Phase II Environmental Site Assessments and is fully entitled for industrial use. This option is well suited for: Industrial real estate investors seeking a high-quality, mission-critical asset Owner-users planning redevelopment or adaptive reuse Strategic groups seeking to control the real estate while evaluating future operational deployment. Turnkey Pharmaceutical Manufacturing Platform Land, Building, and Full API Production Assets For buyers seeking immediate operational capability, the acquisition can be expanded to include the complete pharmaceutical manufacturing platform housed within the facility. This fully integrated asset package includes: Approximately 1.5 million liters of fermentation capacity 200,000 liters of high-pressure / high-temperature reactor capacity Comprehensive downstream processing infrastructure Quality control and analytical laboratories Fully developed utilities and support systems A trained workforce of 50+ operators The facility was designed by Merck, with a layout replicating Merck’s Danville, Pennsylvania site, and is fully permitted and compliant with FDA, EPA, USDA, OSHA, and ISO 13485 requirements. Engineered for commercial-scale API production, the platform offers a compelling strategic advantage: an estimated 18-month fast start-up timeline, compared to approximately five years for a greenfield development. This accelerated path to operation delivers a meaningful time-to-market and capital efficiency advantage for onshore pharmaceutical manufacturing.